Nuvalent, Inc.

NASDAQ:NUVL

63.06 (USD) • At close April 18, 2024
Bedrijfsnaam Nuvalent, Inc.
Symbool NUVL
Munteenheid USD
Prijs 63.06
Beurswaarde 4,040,105,063
Dividendpercentage 0%
52-weken bereik 32.06 - 89.39
Industrie Biotechnology
Sector Healthcare
CEO Dr. James R. Porter Ph.D.
Website https://www.nuvalent.com

An error occurred while fetching data.

Over Nuvalent, Inc.

Nuvalent, Inc., a clinical stage biopharmaceutical company, develops therapies for patients with cancer. Its lead product candidates are NVL-520, a brain-penetrant ROS1-selective inhibitor to inhibit ROS1 fusions that express the normal ROS1 kinase domain without any drug-resistant mutations and remain active in the presence of mutations conferring resistance to approved

Vergelijkbare Aandelen

RAPT Therapeutics, Inc. logo

RAPT Therapeutics, Inc.

RAPT

7.93 USD

IRadimed Corporation logo

IRadimed Corporation

IRMD

40.36 USD

Kinnate Biopharma Inc. logo

Kinnate Biopharma Inc.

KNTE

2.65 USD

Leafly Holdings, Inc. logo

Leafly Holdings, Inc.

LFLY

2.22 USD

Vaxart, Inc. logo

Vaxart, Inc.

VXRT

0.842 USD

Centessa Pharmaceuticals plc logo

Centessa Pharmaceuticals plc

CNTA

10.53 USD

Adicet Bio, Inc. logo

Adicet Bio, Inc.

ACET

2.025 USD

Praxis Precision Medicines, Inc. logo

Praxis Precision Medicines, Inc.

PRAX

46.59 USD

MiMedx Group, Inc. logo

MiMedx Group, Inc.

MDXG

6.16 USD

Financiële Gegevens

Cijfers zijn in miljoenen (USD)

Cijfers zijn in miljoenen (USD)